Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Neoplasm, Residual 1Mesothelioma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Leukemia, Hairy Cell 1Leukemia 1Epstein-Barr Virus Infections 1Carcinoma, Transitional Cell 1

Interventions

LMB-100 4Cyclophosphamide 3fludarabine 2Plicamycin 2Cisplatin 2talazoparib 1pembrolizumab 1olaparib 1fludarabine phosphate 1decitabine and cedazuridine drug combination 1amatuximab 1alvocidib 1aldesleukin 1Surgical Procedures, Operative 1Pentostatin 1Pemetrexed 1Paclitaxel 1Magnetic Resonance Imaging 1Ipilimumab 1Fluorouracil 1Fluorodeoxyglucose F18 1Famotidine 1FANG vaccine 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Dexamethasone 1Depsipeptides 1Cytoreduction Surgical Procedures 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Mesothelioma × Caves × Clear all
NCT04840615 2024-02-02

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
2 enrolled 14 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡